The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues

Peptides

Volumn 29, Issue 11, 2008, Pages 1982-1987

  Kunešová, Gabriela ^a   Hlaváček, Jan ^b   Patočka, Jiří ^c   Evangelou, Alexandra ^d   Zikos, Christos ^d,e   Benaki, Dimitra ^d   Paravatou Petsotas, Maria ^d   Pelecanou, Maria ^d   Livaniou, Evangelia ^d   Slaninova, Jirina ^b  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c UNIVERSITY OF SOUTH BOHEMIA   (Czech Republic)

^d INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^e Biomedica Life Sciences   (Greece)

Author keywords

Alzheimer's disease; Colivelin; Humanin like peptides; Memory; Quinuclidinyl benzilate; Rat

Indexed keywords

COLIVELIN; HUMANIN DERIVATIVE; HYBRID PROTEIN; NEUROPROTECTIVE AGENT; QUINUCLIDINYL BENZILATE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DRUG ACTIVITY; IN VIVO STUDY; MALE; MAZE TEST; MEMORY DISORDER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPATIAL MEMORY;

ANIMALS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAZE LEARNING; MEMORY DISORDERS; NEUROPROTECTIVE AGENTS; ORIENTATION; PEPTIDES; QUINUCLIDINYL BENZILATE; RATS; RATS, WISTAR;

MUS; RATTUS;

EID: 54149087626     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.06.019     Document Type: Article

References (31)

1. In: Afifi A.A., and Azen S.P. (Eds). Statistical analysis and computer oriented approach. 2nd ed. (1979), Academic Press, New York 442-445
2. Albanus L. Studies on central and peripheral effects of anticholinergic drugs. FOA Rep 4 (1970) 1-17
3. Arakawa T., Niikura T., Arisaka F., and Kita Y. Activity-dependent neurotrophic factor, ADNF, determines the structure characteristics of colivelin, a fusion protein of ADNF9 and humanin analog. J Pep Sci 14 (2008) 631-636
4. Baldini C, Formaggio F, Crisma M, Broxterman QB, Kaptein B, Toniolo C. Preferred conformation of tert-leucine Peptides. In: Fridkin M, Flegel M, Gilon C, Slaninova J, editors, Peptides 2004. Proceedings of the third IPS and 28th EPS, Prague 2004. Israel: KENES; 2005. p. 995-6.
5. Bartus A.T., Dean R.L., Beer B., and Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (1982) 408-417
6. Blennow K., de Leon M.J., and Zetterberg H. Alzheimer's disease. Lancet 368 (2006) 387-403
7. In: Bureš J., Burešová O., and Huston J. (Eds). Techniques and basic experiments for the study of brain and behavior (1979), Elsevier, Amsterdam 147-150
8. Chiba T., Yamada M., Hashimoto Y., Sato M., Sasabe J., Kita Y., et al. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo. J Neurosci 25 (2005) 10252-10261
9. Chiba T., Yamada M., Sasabe J., Terashita K., Aiso S., Matsuoka M., et al. Colivelin prolongs survival of an ALS model mouse. Biochem Biophys Res Commun 343 (2006) 793-798
10. Chiba T., Nishimoto I., Aiso S., and Matsuoka M. Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide colivelin. Mol Neurobiol 35 (2007) 55-84
11. Daiello L.A. Current issues in dementia pharmacology. Am J Manage Care 13 (2007) S198-S202
12. Evangelou A., Zikos C., Livaniou E., and Evangelatos G.P. High-yield, solid-phase synthesis of humanin, an Alzheimer's disease associated, novel 24-mer peptide which contains a difficult sequence. J Pept Sci 10 (2004) 631-635
13. Hashimoto Y., Niikura T., Tajima H., Yasukawa T., Sudo H., Ito Y., et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and abeta. Proc Natl Acad Sci USA 98 (2001) 6336-6341
14. Hashimoto Y., Ito Y., Niikura T., Shao Z., Hata M., Oyama F., et al. Mechanisms of neuroprotection by a novel rescue factor humanin from Swedish mutant amyloid precursor protein. Biochim Biophys Res Commun 283 (2001) 460-468
15. Kariya S., Takahashi N., Ooba N., Kawahara M., Nakayama H., and Ueno S. Humanin inhibits cell death of serum-deprived PC12h cells. Neuroreport 13 (2002) 903-907
16. Kawasumi M., Hashimoto Y., Chiba T., Kanekura K., Yamagishi Y., Ishizaka M., et al. Molecular mechanisms for neuronal cell death by Alzheimer's amyloid precursor protein-relevant insults. Neurosignals 11 (2002) 236-250
17. 3] quinuclidinyl benzilate binding to muscarinic cholinergic receptors in the developing human brain-stem. J Comp Neurol 362 (1995) 350-367
18. Krejčová G., Kassa J., and Vachek J. Effects of atropine and the oxime HI-6 on low-level sarin-induced alteration of performance of rats in a T-maze. Acta Med (Hradec Králové) 45 (2002) 107-110
19. Krejčová G., Patočka J., and Slaninová J. Effect of humanin analogues on experimentally induced impairment of spatial memory in rats. J Pept Sci 10 (2004) 636-639
20. 14]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br J Pharmacol 134 (2001) 1597-1599
21. Matsuoka M., Hashimoto Y., Aiso S., and Nishimoto I. Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis. CNS Drug Rev 12 (2006) 113-122
22. Mezey Sz, Székely A.D., Bourne R.C., Kabai P., and Csillag A. Changes in binding to muscarinic and nicotinic cholinergic receptors in the chick telencephalon, following passive avoidance learning. Neurosci Lett 270 (1999) 75-78
23. Nieoullon A. Alzheimer's disease: neurobiological advances supporting proposals for new therapeutical approaches. J Appl Biomed 2 (2004) 123-130
24. Niikura T., Hashimoto Y., Tajima H., and Nishimoto I. Death and survival of neuronal cells exposed to Alzheimer's insults. J Neurosci Res 70 (2002) 380-391
25. Niikura T., Tajima H., and Kita Y. Neuronal cell death in Alzheimer's disease and neuroprotective factor humanin. Curr Neuropharmacol 4 (2006) 139-147
26. Patočka J., Slaninova J., and Kunešová J. Neuroprotective peptides as drug candidates against Alzheimer's disease. J Appl Biomed 3 (2005) 67-73
27. Piccioto M.R., and Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol 53 (2002) 641-655
28. Schneck H.J., Rupreht J., Waldvogel H.H., and Hundelshausen B.V. The central anticholinergic syndrome. J Anaesth Clin Pharm 11 (1995) 267-273
29. Tajima H., Niikura T., Hashimoto Y., Ito Y., Kita Y., Terashita K., et al. Evidence for in vivo production of humanin peptide, a neuroprotective factor against Alzheimer's disease-related insults. Neurosci Lett 324 (2002) 227-231
30. Terashita K., Hashimoto Y., Niikura T., Tajima H., Yamagishi Y., Ishizaka M., et al. Two serine residues distinctly regulate the rescue function of humanin, an inhibiting factor of Alzheimer's disease-related neurotoxicity: functional potentiation by isomerization and dimerization. J Neurochem 85 (2003) 1521-1538
31. Yamada M., Chiba T., Sasabe J., Terashita K., Aiso S., and Matsuoka M. Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. Neuropsychopharmacology 33 (2008) 2020-2032